NKTX
Price
$5.27
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
48 days until earnings call
ZYME
Price
$12.52
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
Ad is loading...

NKTX vs ZYME

Header iconNKTX vs ZYME Comparison
Open Charts NKTX vs ZYMEBanner chart's image
Nkarta
Price$5.27
Change-$0.00 (-0.00%)
Volume$306.1K
CapitalizationN/A
Zymeworks
Price$12.52
Change-$0.00 (-0.00%)
Volume$631.81K
CapitalizationN/A
View a ticker or compare two or three
NKTX vs ZYME Comparison Chart
Loading...
NKTX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
NKTX vs. ZYME commentary
Sep 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NKTX is a Hold and ZYME is a Buy.

COMPARISON
Comparison
Sep 20, 2024
Stock price -- (NKTX: $5.27 vs. ZYME: $12.52)
Brand notoriety: NKTX and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NKTX: 50% vs. ZYME: 75%
Market capitalization -- NKTX: $371.84M vs. ZYME: $873.88M
NKTX [@Biotechnology] is valued at $371.84M. ZYME’s [@Biotechnology] market capitalization is $873.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $599.73B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NKTX’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • NKTX’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, both NKTX and ZYME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NKTX’s TA Score shows that 3 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).

  • NKTX’s TA Score: 3 bullish, 6 bearish.
  • ZYME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than NKTX.

Price Growth

NKTX (@Biotechnology) experienced а -17.91% price change this week, while ZYME (@Biotechnology) price change was +3.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.38%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1.46%.

Reported Earning Dates

NKTX is expected to report earnings on Nov 06, 2024.

ZYME is expected to report earnings on May 08, 2023.

Industries' Descriptions

@Biotechnology (+7.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZYME($874M) has a higher market cap than NKTX($372M). ZYME YTD gains are higher at: 20.500 vs. NKTX (-20.152). ZYME has higher annual earnings (EBITDA): -105.32M vs. NKTX (-115.21M). ZYME (330M) and NKTX (325M) have equal amount of cash in the bank . ZYME has less debt than NKTX: ZYME (20.1M) vs NKTX (85.6M). ZYME has higher revenues than NKTX: ZYME (62.7M) vs NKTX (0).
NKTXZYMENKTX / ZYME
Capitalization372M874M43%
EBITDA-115.21M-105.32M109%
Gain YTD-20.15220.500-98%
P/E RatioN/AN/A-
Revenue062.7M-
Total Cash325M330M98%
Total Debt85.6M20.1M426%
FUNDAMENTALS RATINGS
ZYME: Fundamental Ratings
ZYME
OUTLOOK RATING
1..100
24
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
74
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NKTXZYME
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 15 days ago
85%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
NKTX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMBKX48.150.13
+0.27%
RMB Mendon Financial Services A
MAILX20.21N/A
N/A
BlackRock International Instl
CSVFX20.81-0.05
-0.24%
Columbia International Div Inc Inst
MKVGX14.70-0.06
-0.41%
MFS International Large Cap Value R4
OBEMX12.14-0.06
-0.49%
Oberweis Emerging Markets Investor

NKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been closely correlated with NTBL. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NKTX jumps, then NTBL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
-2.23%
NTBL - NKTX
67%
Closely correlated
-5.43%
FATE - NKTX
45%
Loosely correlated
-3.00%
ICCC - NKTX
43%
Loosely correlated
-2.96%
ASMB - NKTX
42%
Loosely correlated
-0.11%
ZYME - NKTX
39%
Loosely correlated
+1.79%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with BEAM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
+1.79%
BEAM - ZYME
45%
Loosely correlated
-0.27%
RXRX - ZYME
45%
Loosely correlated
+2.07%
RCKT - ZYME
44%
Loosely correlated
-4.40%
ABSI - ZYME
43%
Loosely correlated
+0.76%
CRSP - ZYME
43%
Loosely correlated
-0.64%
More